Astellas Joins With Cytori Of U.S. In Adipose Stem Cell Research
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma and U.S.-based Cytori Therapeutics have joined in a stem-cell research effort that calls for Astellas to buy $10 million of Cytori stock